A true bifurcated lesion in coronary atherosclerotic disease is present in approximately 15% of patients referred for percutaneous coronary intervention (PCI). 1 The percutaneous approach to this especially complex scenario has been faced in many different ways depending on the techniques available at any particular time. [2] [3] [4] In the last few years, the introduction of drug-eluting stents (DES) has remarkably improved the outcome in bifurcation lesions compared with using baremetal stents (BMS), resulting in fewer adverse events and lower main branch (MB) restenosis rates. [5] [6] [7] However, the most suitable approach to the side branch (SB) remains uncertain. Although the initial 'provisional' stenting technique (i.e. stenting of the SB after MB stenting only in cases of suboptimal or inadequate result) is probably the prevailing approach, the four stent techniques that allow the stenting of both branches (i.e. crush, V, T, culottes) are appealing. However, even if the strategy of stenting both branches when the SB stenosis is suitable for stenting is promising, data in the literature indicate that clinical outcomes are better if routine usage of the two-stent strategy is avoided. 8 The introduction of dedicated stents may be supposed to be an attractive strategy for approaching the different types of bifurcation lesion. These stents are specifically designed to provide good deliverability, secured access to the SB and complete coverage of the lesion site without double/triple layers of stent struts. They also incorporate the benefits of drug elution and ensure drug availability to all diseased surfaces. The objective of the observational multicentre Nile Croco Registry was to assess the angiographic and six-month clinical results of a cohort of patients with bifurcation lesions who underwent PCI with dedicated stents. • stable, unstable angina or silent ischaemia;
Methods

Patients and Lesions
• presumed new bifurcation lesion in a main vessel with a reference diameter ≥2.5mm (visually assessed); and
• an SB diameter ≥2.0mm.
Patients with two-or three-vessel disease were included if the other vessel lesions could presumably be successfully treated by PCI or were not tributary for either PCI or coronary bypass graft (CABG). In addition, patients with other lesions in the same vessel were included if these were proximal to the bifurcation lesion.
The major exclusion criteria were:
• presence of non-cardiac severe pathology or life expectancy of less than six months;
• bifurcation lesion type 0,0,1 according to the Medina Classification 9 (type 4b according to Massy class);
• presence of thrombus in the target lesion;
• severely tortuous coronary vessel;
• calcifications proximal to the target lesion; and
• left main coronary lesion or left anterior descending artery (LAD) lesion involving the ostia.
Study Device
The Nile Croco ® intracoronary stent system consists of an 18mm balloon-expandable chromium-cobalt BMS pre-mounted on a dedicated delivery system with two independent balloons, each with a rapid-exchange lumen for the two guidewires required. The MB balloon is available in diameters of 2.5, 3.0 and 3.5mm, and the SB balloon in diameters of 2.0, 2.5 and 3.0mm. There are five devices available using different combinations: MB 2.5 SB 2.0, MB 3.0 SB 2.0, ≥75mg/day and clopidogrel ≥75mg/day for at least one month.
End-points and Definitions
The primary end-points were stent placement success (the stent with the delivery system reaching the desired position at the carina of the bifurcation) and angiographic success of the MB and SB. Success was considered complete if MB residual stenosis was <30% and SB residual Secondary end-points were in-hospital and six-month events, including major adverse cardiovascular events (MACEs) and other in-hospital severe adverse events, such as stent occlusion or haemorrhagic complications requiring blood transfusion or surgery. MACEs were defined as cardiac death, Q-wave and non-Q-wave myocardial infarction and target lesion revascularisation (TLR). TLR was defined as MB and/or SB target site revascularisation by either PCI or CABG. All patients were followed up by a phone call after previous informed consent. Table 1 , and bifurcation and lesion types are described in Table 2 and Figure 3 .
Results
Between
Procedural Data
Most of the devices employed had diameters ranging between 2.5/2.0mm and 3.5/2.5mm (see Table 3 ). Device placement success was achieved in 96% of cases and procedural success in 98% (see Table 2 ). The device could not be delivered in a bifurcated lesion located at the crux cordis of a severely tortuous coronary right artery.
In addition, the lesion had an important calcification component.
Clinical End-point Analysis
There was one confirmed in-hospital MACE in the 93 recruited patients (1%): this was a death due to refractory shock in an 81-yearold patient with three-vessel disease and severe mitral regurgitation who had been rejected for cardiac surgery. The MACE rate at six months in the 85 patients with complete follow-up was 12%. The clinical and/or ischaemia-driven TLR rate was 10.6% (see Table 4 ). One patient died due to unknown reasons during follow-up, 10 days after the stent implantation.
Discussion
The first Nile Croco Registry shows a high rate of device success (96%) and favourable acute and long-term clinical results, as measured by MACE at 180 days. In addition, the procedural success rate achieved (98%) provides a very good index of safety, especially considering the particularly complex lesions that were treated with this novel and dedicated device.
A true bifurcated lesion in coronary atherosclerotic disease is present in approximately 15-25% of patients. The percutaneous approach to this Clinical and Procedural Evaluation of the Nile Croco ® Dedicated Stent for Bifurcation particularly complex scenario has been addressed in many ways depending on the techniques available at the time. Thus, the angiographic result achieved using the initial simple balloon technique 1, 2 was improved with the advent of the kissing-balloon technique, which minimises the plaque shift to the SB. 3, 4 Thereafter, the athero-ablative techniques (rotational and directional atherectomy) reduced the TLR rate, but increased the procedural complications after the percutaneous approach. [5] [6] [7] Next, the use of stents for the scaffolding of the plaque became the treatment of choice. Although the use of one or two BMS for the treatment of bifurcation lesions was initially successful, this method is now associated with high restenosis rates regardless of the technique used. 8, 9 Device Success
The first bifurcated stents appeared in the 1990s, but their rigidity and poor profile were associated with a low rate of success. 10 As a consequence, the idea of treating the MB while protecting the SB with a single dedicated stent and delivery system emerged. The first controlled study with angiographic control during follow-up was carried out with the Multi-Link Frontier coronary bifurcation stent system (Guidant Corp., Santa Clara, CA, US). 11 Using the firstgeneration stent, this study reported a 91% device success rate and a very good safety profile (2.9% MACE at one month and 17.1% at six months; 11.4% ischaemia-driven TLR at six months). Other devices developed by various companies have also been studied, showing similar results in the initial feasibility studies. [12] [13] [14] [15] The patients included in the Nile Croco Registry were older than initially expected (mean age 65±12 years; 11% of patients were over 80 years of age). One possible explanation for this is a possible selection bias during recruitment. Thus, the patients included would likely be those who were not optimal candidates for a DES. Although we did not record all prognostic factors to accurately determine the population and arteries risk profile, the prevalence of diabetic patients (22%) as well as the mean diameter of the vessels treated indicate a low risk and thus a favourable population for angiographic success and good clinical outcomes. However, the prevalence of bifurcation lesions involving the LAD (67%) is clearly lower than that reported in previous studies (for example, in the study by Lèfevre et al. the corresponding figure was 80% 11 ) or initial experiences. This should have led to poorer results in our series, since bifurcation lesions involving the LAD have been shown in other studies to be an independent predictive factor for angiographic and clinical success; however, this was not the case in our study.
The SB was stented in only 13% of cases despite the fact that 54% of the lesions involved the SB (on the Medina classification, 43 lesions were 1,1,1 + 1,0,1 and seven were 0,1,1). The rate of final kissingballoon usage (97%) suggests easy SB access, which would have encouraged the operator to stent the SB if the angiographic result had been poor. However, the residual stenosis at the SB was visually estimated at below 30% in 80% of cases. This remarkably beneficial effect of the device in the SB may be related to the design of the dedicated stents. Therefore, the shape and structure of the Nile Croco 
Clinical Outcome
The Nile Croco stent provided favourable acute and long-term clinical results, as measured by MACE at 180 days, compared with other series. [11] [12] [13] [16] [17] [18] The rate of the secondary end-point, MACE at six months, was 11.8%. Ischaemia-driven TLR was necessary in only 9.4% of cases, which is a better outcome rate than that reported in previous studies undertaken with the provisional T stenting approach. 16, 17, [19] [20] [21] [22] The univariate analysis performed has not shown demographic, lesion and procedure differences between those patients who presented MACE during follow-up and those who did not (see Table 5 ), although the small sample size prevents any firm conclusion being made.
Future
Stent thrombosis has recently emerged as a major drawback of DES, and it appears that treatment of bifurcation lesions with a DES is associated with a higher stent thrombosis rate compared with DES treatment of non-bifurcations, [23] [24] [25] and treatment of bifurcation lesions with tubular DES is not a US Food and Drug Administration (FDA)-approved indication and should therefore be considered with caution.
Some dedicated devices with DES for bifurcation have been studied with preliminary results that look promising, 26 but what seems obvious is that the great hope for dedicated stents that will make bifurcation easy for everybody entails looking for the best platform with which to deliver the drug. The Nile Croco stent shows promising results in the acute and mid-term that should encourage its use as a platform for dedicated DES.
Study Limitations
The Nile Croco Registry is a study designed to examine the procedural safety and clinical feasibility of one particular dedicated stent. It does not compare the Nile Croco with other bifurcation lesion treatments and does not have the statistical power to address issues such as predictive factors for MACE during follow-up.
Conclusions
Bifurcation lesions have long been treated with a large variety of stenting approaches, from the simplest to the most complex. Since tubular or conventional stents are not designed to treat bifurcation lesions, these devices frequently jeopardise the SB during and after the procedure, thus increasing the risk of MACE compared with nonbifurcation lesions. Therefore, the dedicated stents may constitute, in the era of DES, a remarkable improvement in the management of these complex lesions. The design of the Nile Croco stent may both improve initial angiographic success and ensure the homogeneous delivery of drug(s). ■
